Significant findings from the highly-anticipated EPIC-STEMI study were presented during a late-breaking scientific session at the recent Transcatheter Cardiovascular Therapeutics (TCT) 2022 Annual Symposium in Boston, MA.
Feature | TCT | Christine Book
Dramatic Cholesterol Reduction from PCSK9 Inhibitor Achieved in EPIC-STEMI Trial

October 17, 2022 — Significant findings from the highly-anticipated EPIC-STEMI study were presented during a late ...

Home October 17, 2022
Home
People with cardiovascular disease still have a high burden of risk factors for severe COVID
News | Coronavirus (COVID-19)
Smoking, Diabetes and Obesity - Not Preexisting Heart Disease - Bigger Risk of COVID-19 Death, Study Finds

October 17, 2022 — A national study suggests that risk factors for cardiovascular disease, such as age, smoking and ...

Home October 17, 2022
Home
Low-cost blood pressure lowering drugs, statins and aspirin widely in the form of a single pill, also known as the polypill. McMaster University
News | Pharmaceuticals
The Polypill Could Avoid Millions of Premature Deaths, Heart Attacks and Strokes Every Year, Say Leading Cardiology Experts

October 17, 2022 — Global Health has paid a deadly price for not using simple, low-cost blood pressure lowering drugs ...

Home October 17, 2022
Home
Allegheny Health Network’s Cardiovascular Institute announced today the expansion of its nationally recognized thoracic surgery program to AHN Wexford Hospital, marking the full-service hospital’s most recent milestone in providing access to the highest level of care to patients living in communities north of Pittsburgh. The program launched under the clinical direction of AHN cardiothoracic surgeon, Hiran C. Fernando, MD.
News | Cardiovascular Surgery
AHN Cardiovascular Institute Expands Thoracic Surgery Program to AHN Wexford Hospital

October 17, 2022 — Allegheny Health Network’s (AHN) Cardiovascular Institute announced the expansion of its nationally ...

Home October 17, 2022
Home
Study data show clinically meaningful impact on quality of life and disease severity, even in the most complex patients
News | Venous Therapies
ABRE Clinical Study 36-Month Data Shows Sustained Effectiveness of Abre Venous Self-Expanding Stent System

October 14, 2022 — Medtronic, a global leader in medical technology, announced the 36-month final results from the ABRE ...

Home October 14, 2022
Home
The HELIOSTAR Balloon Ablation Catheter's unique one-shot balloon technology enables pulmonary vein isolation in 12 seconds, with customized energy delivery and one integrated 3D mapping solution
News | EP Lab
Biosense Webster Launches HELIOSTAR in Europe, the First Radiofrequency Balloon Ablation Catheter, Enabling Physicians to Perform More Efficient Cardiac Ablations

October 14, 2022 — Biosense Webster, Inc., part of Johnson & Johnson MedTech†, today announced the European launch of ...

Home October 14, 2022
Home
Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP testinG, of Heart Failure therapies) study, announced the premature termination of the trial.
News | Cardiovascular Clinical Studies
STRONG-HF Study in Patients Admitted for Acute Heart Failure (HF) Terminated Early for Superior Efficacy

October 14, 2022 — Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid ...

Home October 14, 2022
Home
The data, collected during the transition from intravenous (IV) to oral levosimendan in the open-label extension (OLE) of the HELP (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) trial, were presented at the Heart Failure Society of America (HFSA) Scientific Sessions 2022
News | Heart Failure
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

October 13, 2022 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing, and ...

Home October 13, 2022
Home
the U.S. Patent and Trademark Office has issued to the University of Iowa Research Foundation ("UIRF") U.S. Patent No. 11,414,704 titled COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE, which is exclusively licensed to the Company from UIRF
News | Heart Failure
Cardio Diagnostics Announces Issuance of U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

October 13, 2022 — Cardio Diagnostics, Inc. , a pioneering precision cardiovascular testing company, announced that the ...

Home October 13, 2022
Home
Zach Williams wanted to be a cancer researcher, but quick success in another area refocused his research on cardiovascular science. He was awarded a National Institutes of Health grant to fund his research for two years. Image courtesy of Clayton Metz/Virginia Tech.
News | Heart Failure
Virginia Tech Graduate Student Earns NIH Support to Explore Promising Heart Finding

October 13, 2022 — Zach Williams thought he’d become a cancer researcher when he joined Virginia Tech’s Translational ...

Home October 13, 2022
Home
Videos | TCT
VIDEO: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

At TCT 2022, Deepak Bhatt, MD, MPh, Executive Director of Interventional Cardiovascular Programs, Brigham and Women's ...

Home October 13, 2022
Home
The Delphi study results show Philips’ integrated echocardiography solution provides the tools required for baseline risk stratification and monitoring of cardio-oncology patients as recommended by the latest European Society of Cardiology (ESC) guidelines
News | Heart Failure
Panel of Experts Highlights Clinical and Operational Benefits of Philips’ Integrated Echocardiography Solution

October 12, 2022 — Following the recent European Society of Cardiology (ESC) Congress in Barcelona, Spain last month ...

Home October 12, 2022
Home
Study investigates metformin and other candidate drugs through a network medicine approach
News | Heart Failure
Cleveland Clinic Researchers Identify Diabetes Drug Metformin as Potential Atrial Fibrillation Treatment in Collaborative Research

October 12, 2022 — Cleveland Clinic researchers have identified a common diabetes medication, metformin, as a possible ...

Home October 12, 2022
Home
Renowned Stanford Cardiologist Brings Deep Clinical, Research, and Industry Expertise to Executive Team
News | Cardiovascular Business
HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer

October 12, 2022 — HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ECG ...

Home October 12, 2022
Home
Share Images Automatically, Instantly, and Securely
Sponsored Content | Whitepapers | Archive Cloud Storage
Strategic Planning for Imaging in the Cloud

Change Healthcare’s cloud-native archiving, viewing, and image-sharing solutions can help improve efficiencies in ...

Home October 11, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now